234 related articles for article (PubMed ID: 32467291)
1. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
5. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
9. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
[TBL] [Abstract][Full Text] [Related]
10. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
11. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
12. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
13. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB
BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211
[TBL] [Abstract][Full Text] [Related]
14. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.
Pervin S; Hewison M; Braga M; Tran L; Chun R; Karam A; Chaudhuri G; Norris K; Singh R
PLoS One; 2013; 8(1):e53287. PubMed ID: 23341935
[TBL] [Abstract][Full Text] [Related]
17. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
19. The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.
Ory V; Kietzman WB; Boeckelman J; Kallakury BV; Wellstein A; Furth PA; Riegel AT
Breast Cancer Res Treat; 2018 May; 169(1):47-57. PubMed ID: 29350308
[TBL] [Abstract][Full Text] [Related]
20. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]